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Summary Two human ovarian (OV-MZ-10, OV-MZ-15) and two colon cancer cell lines (CO-MZ-5, CO-MZ-
6) were newly established in permanent cell culture. These cell lines have been maintained in vitro for 5-6
years, the passage number varying from 25 to 228. They were established from ascites or solid tumours at the
time of primary surgery. By clinical and histopathological judgement alone all four cell lines would have been
interpreted as ovarian cancer cell lines. Morphological criteria or the expression of the tumour-associated
antigens CA-125 and CEA allowed no differential diagnosis. Only the analysis of the expression of different
cytokeratins and vimentin enabled us to verify the different origin of the cell lines. Ovarian cancer cell lines, in
contrast to the colon cancer cell lines, are positive for the expression of cytokeratin (CK) 7 and for vimentin.
CK 20 proved to be the marker with the best discrimination. CK 20 was found exclusively in the colon
carcinoma cell lines, but not in the ovarian carcinoma cell lines. The evaluation of cytokeratin expression is a
helpful diagnostic modality in differentiating between adenocarcinoma cell lines derived from ovarian and
colon tumours.
A variety of human ovarian and colon carcinoma cell lines
has been described in the literature (Wolf et al., 1987; Hill et
al., 1987; Giancotti et al., 1989; Rutzky et al., 1979; Shi et
al., 1983). The establishment ofcell lines from human cancers
is a useful tool in investigating their histogenesis and car-
cinogenesis. Such cell lines can also be used for the evalua-
tion of the effectiveness of new anti-cancer drugs (Fanning et
al., 1990; Hills et al., 1989), pharmacologically induced
differentiation (Langdon et al., 1988), trials of overcoming
multidrug resistance or the production of MAbs against
tumour-associated antigens (Miotti et al., 1987). Therefore
the establishment of new cell lines and the definite classifi-
cation of the origin of each cell line are highly important.
Most ovarian and colon carcinoma cell lines are derived from
adenocarcinomas. From a clinical point of view differential
diagnosis may sometimes be difficult on the basis of the
intraoperative situation and the histopathological examina-
tion. After establishment in cell culture many cell lines have
been characterised exhaustively by light and electron micro-
scopy, xenotransplantation, immunohistochemical and bio-
chemical analysis, cytogenetic and flow cytometric analysis
and hormone production. Nevertheless incorrrect
classification of the origin of the cell line cannot be definitely
excluded. This study describes the important role of
intermediate filament and cytokeratin expression in exactly
defining the primary tumour.
Materials and methods
Patient data
OV-MZ-10 This cell line was established in May 1987 from
the malignant ascites of a 61-year-old woman with ovarian
cancer stage FIGO III. A laparotomy with hysterectomy,
bilateral salpingo-oophorectomy, removal of the cul-de-sac
peritoneum, omentectomy and appendectomy was per-
formed. Histologically the tumour was described as a
moderately differentiated serous cystadenocarcinoma. Despite
one course of platinum-containing chemotherapy, the disease
progressed rapidly. The patient received an ileostomy but
died 11 weeks after laparotomy.
OV-MZ-JS In March 1988, the 59-year-old patient had a
laparotomy with hysterectomy, bilateral salpingo-
oophorectomy, removal of the cul-de-sac peritoneum,
omentectomy, appendectomy and lymph node sampling for
ovarian cancer stage FIGO III. Macroscopically, there was
no residual tumour. Histologically a serous cystadenocar-
cinoma of the ovaries was described. The cell line was estab-
lished from the tumour sample of the right ovary. The
patient received six courses of combination chemotherapy
(cisplatin/cyclophosphamide). When clinical complete remis-
sion was obtained, we performed active specific immuno-
therapy (ASI) with intradermal application of virus-modified
(New Castle disease virus) autologous tumour cells. At pre-
sent the patient continues in complete remission.
CO-MZ-S In March 1988, the 43-year-old patient had a
laparotomy after the clinical diagnosis of simultaneous
cancer of the ovary and the sigmoid colon. This was
confirmed intraoperatively. Hysterectomy, bilateral salpingo-
oophorectomy, omentectomy, iliac lymphadenectomy and
partial resection of the sigmoid with end-to-end reanasto-
mosis were performed. The cell line was established from the
tumour of the right ovary. There was no macroscopic
residual tumour. The pathologist described a serous cyst-
adenocarcinoma of both ovaries (pT2k No Mj) and a second
independent tumour of the sigmoid colon (pT2 No), which
corresponded to an ulcerating adenocarcinoma. Post-
operatively the patient received one course of mitomycin C
and seven courses of CMF (cyclophosphamide, methotrexate,
5-fluorouracil). A second-look operation was done in April
1989 and confirmed the complete remission. A few months
later the patient had progressive bone metastasis in the right
hip and received a total prosthetic replacement.
The histological examination now revealed the necrotic
metastasis of an adenocarcinoma without further differenti-
ation. CEA was highly elevated at 495 ng ml-'; CA-125
remained in the normal range. Despite radiotherapy of the
hip and second-line chemotherapy the patient died in
December 1990.
CO-MZ-6 A 73-year-old patient underwent exploratory
laparotomy. Preoperatively CEA was highly elevated at
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216 ng ml-', CA-125 was only moderately elevated at
199 U ml-'. The operative report described the classical
situation of an advanced ovarian cancer with peritoneal car-
cinomatosis and multiple tumour nodules in the mesentery.
The cul-de-sac was padded by tumour. The surgical presenta-
tion did not suggest colon cancer. Preoperatively a barium
enema of the colon had not been performed. Hysterectomy
with bilateral salpingo-oophorectomy was done. The cell line
was established from the left ovary. The pathologist de-
scribed a serous cystadenocarcinoma of the ovaries with
infiltration of the uterus. The endometrium showed adeno-
matous hyperplasia. In view of the age of the patient and the
advanced disease, she received only palliative chemotherapy
with cyclophosphamide. The patient died some months later
because of progressive disease. Clinically there were no signs
of intestinal obstruction.
Establishment ofthe cell lines
After removal of fat and necrotic parts, tumour specimens
were minced into pieces ofapproximately 1 mm3. The cells in
the supernatant were aspirated with a Pasteur pipette and the
remaining tumour fragments minced again. The cells were
subsequently centrifuged three times at 1,000g for Omin.
Effusion cells were harvested by centrifugation at 1,000 g for
10 min, twice resuspended and centrifuged again. The tumour
cells were then transferred to T-30 flasks (Nunc, Roskilde,
Denmark). Culture flasks were initially treated with selective
trypsinisation (trypsin 0.05% w/v, EDTA 0.02% w/v), to
avoid fibroblast overgrowth. In addition, we attempted
mechanical removal of the fibroblasts or selective transfer of
the tumour cells. Routine assays for mycoplasma, fungi and
bacterial contamination were negative.
Culture conditions
The cell lines were cultured on plastic at 37TC in a 5%
carbon dioxide and 95% air atmosphere. In the early phase
of cultivation, the tumour cells were grown in CMRL
medium (Gibco, Karlsruhe, Germany). When the cells could
be serially passaged, they were grown in Dulbecco's modified
Eagle medium (DMEM, Gibco). Both media were supple-
mented with 10% fetal calf serum (FCS) (Gibco), penicillin
(100 U ml'), streptomycin (100pgml-'), 1% (v/v) non-
essential amino acids and sodium pyruvate and L-glutamine
(2mM).
All cell lines were frozen in liquid nitrogen at early pas-
sages and at intervals offive passages with increasing passage
numbers.
Growth parameters
The rate of cellular proliferation was measured in the cul-
tures during the logarithmic growth phase. Tumour cells
(5 x 105) were seeded in 25 cm2 culture flasks and refed on
day 3. From day 3 to day 9, total cell counts were deter-
mined in triplicate with the Neubauer haemocytometer.
Heterotransplantation in nude mice
Tumorigenicity of three cell lines was tested by heterotrans-
plantation in 6- to 8-week-old nu/nu mice (NMRI). The mice
(n = 3 per cell line) were obtained from the Versuchstieran-
stalt (Hannover, Germany). Tumour cells were injected s.c.
into both flanks at an inoculum size of 1 x I07 cells each.
Histological sections of the tumours were stained with
haematoxylin and eosin.
Scanning and transmission electron microscopy
For scanning electron microscopy, the tumour cells were
seeded on glass coverslips, fixed in situ by exposure to 2.5%
phosphate-buffered glutaraldehyde solution (pH 7.2) and
post-fixed in 2% osmium tetroxide solution. After dehydra-
tion in an ascending acetone series, the tumour cell
monolayer was dried by the critical point method and sput-
tered with gold. Electron photomicrographs were taken with
a PSEM 501 Philips scanning electron microscope. For trans-
mission electron microscopy, tumour tissue and cells were
fixed by exposure to 2.5% sodium cacodylate-buffered
glutaraldehyde solution (0.1 mol, pH 7.4) and post-fixed in
1% sodium cacodylate-buffered osmium tetroxide solution
(0.1 mol, pH 7.4) prior to Epon embedding. These sections
were contrasted with uranyl acetate and lead citrate. Electron
photomicrographs were taken with an EM 410 Philips trans-
mission electron microscope.
Analysis ofintermediatefilament (IF) proteins by
immunocytochemistry
Cells were grown on microscope slides to subconfluent den-
sity, rinsed with phosphate-buffered saline (PBS) and fixed in
methanol (5 min, - 20C) and subsequently briefly in acetone
(- 20C). After air drying, the slides were stored at - 20C.
The immunocytochemical method used was the indirect
immunoperoxidase procedure (Franke & Moll, 1987). The
following MAbs against IF proteins were applied: (1) MAb
Ks 18.174 specific for cytokeratin (CK) 18 (commercially
available through Progen, Heidelberg, Germany); (2) MAb
Ks 19.2-Z105 against CK 19 (Franke & Moll, 1987; Pro-
gen); (3) MAb CK 7 against CK 7 (Boehringer, Mannheim,
Germany); (4) MAb AE 14 against CK 5 (Lynch et al., 1986;
kindly provided by T.T. Sun, New York); (5) MAb E 3
against CK 17 (Troyanovsky et al., 1989; kindly provided by
S.M. Troyanovsky, Moscow, Russia); (6) MAb 6B10 specific
for CK 4 (obtained from Euro-Diagnostics, Apeldoorn, The
Netherlands); (7) MAb IT-Ks20.2 and IT-Ks20.11 against
CK 20 (Moll et al., 1990; Progen); (8) MAb VIM-9 against
vimentin (Pitz et al., 1987; Viramed, Martinsried, Germany).
Determination ofCA-125 and CEA
In the supernatant The secretion of CA-125 and CEA in the
supernatant was determined in proliferating and resting cells.
The supernatant of exponentially growing cell cultures was
collected on days 2, 4, 6 and 8 and the cells were counted.
The supernatant was centrifuged at 1,000g for 10min and
stored at - 20°C until tested. The CA-125 level in the super-
natant was determined by a solid-phase radioimmunoassay
(RIA) (CIS, Dreieich, Germany), the CEA level by a solid-
phase enzyme immunoassay (EIA) (Hoffmann-LaRoche,
Basle, Switzerland).
By FACScan analysis Murine monoclonal antibodies
directed against CA-125 and CEA were purchased from CIS
and Dianova-Immunotech (Marseille, France) respectively.
Normal mouse IgGI was purchased from Becton Dickinson,
FITC-conjugated goat anti-mouse IgG was obtained from
Coulter (Krefeld, Germany). Quantitation of the tumour-
associated surface antigens was performed on a FACScan
cytofluorimeter. The cells were gently harvested by exposure
to EDTA (0.05%) and filtered through a 30 tLm nylon mesh.
Cells (1 x 106) suspended in PBS were exposed to the specific
or control antibody for 30 min on ice. The cells were then
washed twice and resuspended in PBS containing an appro-
priate FITC-conjugated second MAb. After another 30min
of incubation on ice, cells were washed twice in PBS and
analysed at 488 nm.
Results
Table I summarises the important clinical and biological
characteristics of the cell lines. The lines have been in culture
for 5-6 years, the passage numbers varying from 25 to 228.
In contrast to the slowly proliferating colon cancer cell lines,
the two ovarian cancer cell lines are proliferating very fast.
One line was established from ascites, three lines from solid
tumours. All lines were established from untreated patients at424 V.J. MOBUS et al.
Table I Clinical and biological characteristics of the cell lines and the original tumours
Survival of
Initiation patients in Median Tumorigenesis in Current
Cell line of culture Source months doubling time nude mice passage
OV-MZ-10 5.87 Ascites 3 months 27 h Yes 228
OV-MZ-15 3.88 Ovary 5 years + 48 h No 120
CO-MZ-5 3.88 Ovary 33 months 17 days No 25
CO-MZ-6 4.87 Ovary 8 months 11 days ND 38
ND, not done.
-6,S
Figure 1 a c, Ultrastructural aspects of the ovarian carcinoma cell line OV-MZ-15; loosely apposed tumour cells a, occasionally
exhibiting cytoplasmic deposits ofmonoparticulate glycogen b, and typical desmosomes c. d-f, Ultrastructural aspects of the colon
carcinoma cell line CO-MZ-5; loosely apposed tumour cells d, with microvilli-like cytoplasmic protrusions e and deposits of f
monoparticulate glycogen (star) and desmosomes (arrow). a,d, bar = 5jsm; b,e,f, bar = 1 jAm; c, bar = 0.5tLm.
the time of primary surgery. The survival of the patients
ranges from 3 months to. more than 5 years.
One out of three lines (OV-MZ-10) produced a slow-
growing tumour in nude mice after s.c. transplantation of
1 x IO0 viable tumour cells. The tumours grew in all three
inoculated animals and reached a diameter of 6-10 mm after
14 weeks. OV-MZ-10 cells formed a moderately differentiated
papillary adenocarcinoma, closely resembling the originalDIFFERENTIATION BETWEEN OVARIAN AND COLON CARCINOMA CELL LINES 425
Table II Expression of various cytokeratin polypeptides and vimentin in the four carcinoma cell lines as determined by immunoperoxidase
microscopy
Stratified epithelial cytokeratins Simple epithelial cytokeratins
CK 4 CK 5 CK 17 CK 7 CK 18 CK 19 CK 20 Vimentin
OV-MZ-10 (p 34) - - (+) +++ +++ +++ - +++
OV-MZ-15 (p 41 - - ++ ++ - + _ +
CO-MZ-5 (p 12) (+) - + - + + + + + + + +a (+)b
CO-MZ-6 (p 26) - - - - + + + + + + +c -
The proportions of immunostained cells were assessed semiquantitatively and scored as follows: -, negative; (+), <5% of cells positive; +,
5-20% of cells positive; + +, 21- 80% of cells positive; +++, >80% positive. aApproximately 70% of cells positive. bSparse cells at the
periphery of cell colonies positive. cApproximately 30% of cells positive.
Morphological characteristics ofthe cell lines
!. i iThe cell size of the ovarian cancer cells was larger by phase-
contrast microscopy and they expanded more diffusely than
the colon cancer cell lines, which grew in compact colonies.
Transmission electron microscopy revealed only minor
differences between the ovarian (Figure la-c) and colonic
(Figure Id-f) carcinoma cell lines. The tumour cells were
separated by narrow intercellular spaces bridged by cytoplas-
mic, interdigitations and typical desmosomes (Figure Ic and
.... Occasionally, the tumour cells exhibited intracellular
lumina, indicating their origin from gland-forming adenocar-
cinomas. The cytoplasm of the cells was rich in poly
ribosomes and mitochondria, whereas profiles of rough *~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~.!...............
8 0 0 0'liW b500 T ct elX ik ndolsi rienticulumt were hihypsiteldom sheen Dexpoesits of
...... ~!_ h 00Wg ; Xmonoparticulate glycogen were occasionally observed in
i tovarian and colon carcinoma cells (Figure lb and fhe the
colon carcinoma cells sometimes showing microvillus-like
cytoplasmic protrusions (Figure Ile). The nuclei were
Ovarian...... moderately irregular in shape, often exhibiting prominent
nucleoli.
CO-MZ-5 d-f andCO-MZ-6g-iwerestainePatterns ofIFproteins
Cell lines Results concerning the expression of individual
CK polypeptides and vimentin are summarised in Table II
and illustrated in Figure 2. All four cell lines strongly ex-
pressed the general sinple epithelial CK polypeptides CK 18
pattern, withmajor f or minoricellpopulationsbeingand 19, along with generally poor expression of stratified
epithelial CKs. Differences were observed with respect to the
~~~selective simple epithelial CKs: CK 7 was only expressed in
ovarian carcinoma cell lines but was completely absent fo
the colon carcinoma cell lines. In contrast, CK 20 has been
the ovarian carcinoma lines. Vimentin was strongly expressed
.uor The O ZaO 5 d g in the ovarian cell lines but was essentially absent from the
colon carcinoma cell lines.
In addition, we examined the expression of the CK
polypeptides and vimentin in the three colon cancer cell lines
CO-MZ-l, -2 and -4, which were also established by our
~~~~~~~roup (results not shown). As expected, these three colon
cancercelllineswerealsonegativefortheexpressionofCK
7 and vimentin, but were highly positive for the expression of
Figure 2 shows the immunocytochemical cytokeratin typ- I ~~~~ingof the ovarian cancer cell line OV-MZ-l15 and the two
colon cancer cell lines. Positive immunocytochemical staining
Figure 2 Immunocytochemical cytokeratin typing of the car- generally consisted of a distinctly fibrillar cytoplasmic pat- cinoma cell lines. Using indirect immunoperoxidase microscopy, tern.
ovarian carcinoma cells OV MZ 15 a-c, colon carcinoma cells
CO-MZ5 d-f and CO-MZ-6 g-i were stained for CK 18 a,d, rgnltmusTbeIIsosteepeso ftems CK 19 g, CK 17 b,e,h, and CK 20 c,fi Note expression of CK 7 imoriginal tumouspale e iteial shtowsrathesan exrsioentiof i theeos only in OV MZ- 15 b and selective expression of CK 20 in CO imortgiantusimple epThelialulcytokerainscmlt andrvimenti winthe MZ-5 f and CO MZ-6 i Also note the heterogeneous CK 20 oiia uor.Terslsaei opeeareetwt
pattern with major f or minor i cell populations being immuno- the immunocytochemical staining of the derived cell lines.
stained. Again CK 7 and vimentin were expressed by the original
tumours of ovarian origin but were completely absent in
colon cancer. In contrast, CK 20 was only found in 4% of
cells in one ovarian cancer, but was highly expressed in the
tumour. The cell lines OV MZ 15 and CO MZ-5 did not give original colon cancer. Concerning CO-MZ-5 the original sig-
rise to transplant tumours within the observation period. A moid cancer and the metastasis of the ovary were both
nude mice inoculation was not performed with the cell line consistently positive in 50% and 45% of the cells respec-
CO MZ-6. tively.426 V.J. MOBUS et al.
Table III Expression of simple epithelial cytokeratin and vimentin
in the original tumours of the established cell lines
Simple epithelial cytokeratins
CK 7 CK 19 CK 20 Vimentin
OV-MZ-10 + + +) ++
OV-MZ-15 +++ +++ _ +-+
CO-MZ-5
Sigmoid - + + + + + -
Ovary _ ++ ++
CO-MZ-6 - +++ +++ -
The proportions of immunostained cells were assessed
semiquantitatively and scored as follows: -, negative; (+), <5% of
cells positive; +, 5-20% of cells positive; + +, 21-80% of cells
positive; + + +,>80% positive.
Determination ofCA-125 and CEA
Table IV shows the expression of the tumour-associated
antigens in vivo and in vitro. In three patients the
preoperative serum levels were determined. CA-125 was
elevated in 2/3 patients, CEA in 3/3 patients. This was in
accordance with the IRS score of the original tumour. The
original sigmoid cancer and the metastasis of the ovary of
CO-MZ-5 both showed an identical staining.
We also performed a FACScan analysis of the cell lines.
The percentage of positive cells varied from 0 to 48% for
CA-125 and from 0 to 28% for CEA.
Discussion
Two human ovarian and two colon carcinoma cell lines have
been newly established in permanent cell culture.
By clinical criteria, three patients were treated as ovarian
cancer patients and one patient was diagnosed as having
simultaneous ovarian and colon cancers. Because the cell line
of this patient was established from the ovarian tumour, in
the beginning all four lines were classified as ovarian cancer
cell lines in our laboratory. The clinical diagnosis was fully
confirmed by histopathological examinations. The tumours
of the two patients that gave rise to the ovarian cancer cell
lines OV-MZ-10 and OV-MZ-15 were correctly described as
serous cystadenocarcinomas. The colon cell line CO-MZ-5
was derived from a patient with a tumour of both ovaries
and a second tumour of the sigmoid colon. The pathologist
described a serous cystadenocarcinoma of both ovaries and a
second independent primary ulcerating adenocarcinoma of
the colon. The tumour from which the colon cell line CO-
MZ-6 was established was originally considered to be a
serous cystadenocarcinoma of the ovaries. The clinical course
of CO-MZ-5, however, was unusual for ovarian cancer. After
a histopathologically confirmed complete remission, the
patient died ofprogressive bone metastasis. The other patient
died 8 months after diagnosis despite palliative chemotherapy
of progressive intraperitoneal disease, compatible with pro-
gressive ovarian cancer.
Transmission electron microscopy showed only minor
differences between the ovarian and colon carcinoma cell
lines. The epithelial nature of the cell lines was confirmed by
the presence of numerous desmosomes and occasional intra-
cellular gland-like spaces. The inability to produce transplant
tumours in nude mice, which became evident for the cell lines
OV-MZ-15 and CO-MZ-5, did not argue against the carcino-
matous derivation of these cell lines, since this phenomenon
has also been reported in other human tumour cell lines (Hill
et al., 1987). The slow median doubling time of 17 days may
have impeded the tumorigenesis of CO-MZ-5.
Only cytokeratin analysis enabled us to unmask the true
origin of the two colonic carcinoma cell lines. The consistent
expression of the simple epithelial CK polypeptides, CK 18
and CK 19, and the poor expression of stratified epithelial
CKs provided support for the epithelial nature and deriva-
tion of the four lines and was in accordance with the fact
that these cell lines were derived from adenocarcinomas.
The simple epithelial cytokeratin CK 7 was only expressed
in ovarian carcinoma cells and was completely absent from
colon carcinoma cell lines. This reflects exactly the situation
in corresponding in vivo carcinomas (Moll et al., 1982; 1983;
1992; Osborn et al., 1986; van Niekerk et al., 1991): colon
carcinomas are essentially CK 7 negative (for exceptions, see
van Niekerk et al., 1991; Moll et al., 1993); ovarian car-
cinomas are constantly positive. This was confirmed by our
study. The colon cancer cell lines, the corresponding original
tumour and the metastasis in the ovary were CK 7 negative,
whereas the ovarian cancer cell lines and the original
tumours were CK 7 positive. Thus, CK 7 can be used as a
good discriminating marker, although it should be noted that
occasionally cell lines derived from ovarian carcinoma may
lose CK 7 expression (M6bus et al., 1992).
CK 20 has been found exclusively in the colon carcinoma
cell lines but not in the ovarian carcinoma lines. This result
also completely agreed with the clinical situation in 'in situ'
tumours. CK 20, which only recently has been introduced as
a new CK polypeptide (Moll et al., 1990), shows a very
restricted tissue specificity and is only expressed at significant
levels in the mucosa of small and large intestine, in the
gastric foveolar epithelium, in the umbrella cells of the
urothelium and in epidermal Merkel cells. This specificity is
largely maintained in the corresponding carcinomas: in an
extended immunohistochemical screening, 89/92 cases of colo-
rectal adenocarcinomas expressed CK 20, whereas 31 out of
34 serous, endometrioid, anaplastic and clear cell ovarian
carcinomas were completely negative and the other three
were essentially negative for this CK (Moll et al., 1992). The
expression of CK 20 is a very stable feature of normal and
malignant intestinal epithelium since it is preserved in most
metastases of colorectal carcinomas as well as in most estab-
lished colon carcinoma cell lines (Moll et al., 1990, 1992;
1993). This statement was fully confirmed by the results of
our experiments. The original tumours of the colon cancer
cell lines were positive for CK 20, as was the metastasis in
the ovary. The two reported colon cancer cell lines in this
paper and three more colon cell lines, also established by our
group, were without exception also positive for CK 20 and
negative for CK 7. The original tumours of the reported
ovarian cancer cell lines as well as the cell lines themselves
were negative.
The only point to be considered when using CK 20 as a
marker for particular pathways of epithelial differentiation,
notably of the intestinal type, is the fact that ovarian
mucinous tumours (both adenomas and carcinomas) also
Table IV Preoperative tumour marker level in the patient serum, IRS score of primary tumour and percentage of FACScan-positive cells in
cell culture
Patient's serum level preoperatively IRS score ofprimary tumour FACScan-positive cells (%)
Cell line CA-125 (Uml-') CEA (ngml-') CA-125 (Uml-') CEA (ng ml-) CA-125 (Uml-') CEA (ngml-')
OV-MZ-10 227 10 4 4 32 0
OV-MZ-15 nd nd 4 1 48 0
CO-MZ-5 5 245 0 6 (ovary) 0 0
0 8 (sigmoid)
CO-MZ-6 199 216 2 12 10 28
ND, not determined.DIFFERENTIATION BETWEEN OVARIAN AND COLON CARCINOMA CELL LINES 427
express this CK (Moll et al., 1992). A normal ovarian cell
expressing CK 20, however, has not yet been discovered.
Ovarian mucinous carcinomas and colorectal adenocar-
cinomas are similar also with respect to other markers in-
cluding especially CEA positivity. In the present cases the
possibility that the two colon cancer cell lines were estab-
lished from mucinous ovarian cancer could be excluded on
the basis ofclinical and histopathological findings and by the
critical review of the original histology by two independent
pathologists. Thus the different patterns of expression of CK
20 enabled us to definitely identify two supposed ovarian
carcinoma cell lines as colon carcinoma lines. Retrospectively
the supposed independent ovarian tumour of CO-MZ-5 has
to be considered a primary metastasis of the colon cancer.
The clinical presentation of CO-MZ-6 was difficult to
evaluate. The cul-de-sac was padded by tumour and a
barium enema of the colon had not been performed
preoperatively. CK analysis demonstrated that this patient's
tumour was incorrectly classified as ovarian cancer.
An additional discriminative marker is vimentin, which
was strongly expressed in the ovarian carcinoma cell lines but
essentially absent from the colon cell lines. This is again in
very good agreement with the 'in situ' situation (Azumi &
Battifora, 1987; Moll et al., 1991). In previous studies,
ovarian cancer cell lines all expressed vimentin, albeit at
different levels (Mobus et al., 1992).
The four cell lines also differed in their expression of
tumour-associated antigens. In contrast to the detection of
CK 20, however, the different levels of expression of these
markers had no impact on differential diagnosis. It is well
known that CA-125 is the leading tumour marker of serous
cystadenocarcinoma and undifferentiated carcinoma of the
ovary. In advanced disease approximately 80% of the
patients have an elevated marker (Soper et al., 1990). In
contrast, CEA shows elevated serum levels in only 30-40%
of ovarian cancer patients, mostly in cases of advanced
disease and especially in poorly differentiated or mucinous
carcinoma, which was excluded in our cell lines by histo-
pathological examination of the original tumour. In colon
cancer CEA is consistently the most important marker.
It is obvious that in the serum of the two colon cancer
patients CEA was strongly elevated preoperatively. However,
in one of these patients (CO-MZ-6), CA-125 was also
significantly elevated, supporting the initial diagnosis of
ovarian carcinoma. In the one ovarian cancer cell line tested
CA-125 was elevated much more than CEA. The results of
the serum values agreed with the IRS score of the primary
tumour.
The results of the FACScan analysis for CA-125 were in
agreement with the patient's serum level and the IRS score of
the original tumour. Concerning CEA, the cells of OV-MZ-
10 and CO-MZ-5 were negative by FACScan analysis
although the lines were established from patients with
preoperatively elevated CEA serum levels and a positive IRS
score of the primary tumour. This observation suggests the
possibility of a clonal selection of CEA-negative tumour cells
under the conditions of long-term in vitro culture. An
analogous loss of CA-125 expression after prolonged cultur-
ing of ovarian carcinoma cell lines has also been described by
van Niekerk et al. (1988) and by our group (M6bus et al.,
1992).
Our group has established 40 new ovarian cancer cell lines
in the past 8 years. They were all characterized exhaustively,
including morphological and CK analysis. CK analysis
revealed two cell lines (5%) which were highly positive for
the expression ofCK 20 and thus could be identified as colon
cancer lines. Neither the clinical presentation or histological
examination of the original tumour nor the expression of
tumour-associated antigens was decisive in the differential
diagnosis between colon and ovarian cancer.
Permanent cell lines are valuable tools in the examination
of the biological properties of human cancers of different
origins. Therefore it is important to define the origin of each
cell line as exactly as possible. Although CK analysis is not a
universal tool differentiating between all adenocarcinomas,
we believe that the examination of any established adenocar-
cinoma cell line with respect to its cytokeratin expression
pattern is warranted to further reduce the hazards of mis-
classification.
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